Beta Bionics (BBNX) EBITDA (2024 - 2026)

Beta Bionics has disclosed EBITDA across 3 years of filings, most recently posting -$22.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$22.4 million, up 21.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.8 million (up 5.59% YoY), and the FY2025 annual result was -$72.9 million, down 32.89% from the prior year.
• EBITDA came in at -$22.4 million for Q1 2026 at Beta Bionics, down from -$13.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.7 million in Q3 2024 to a low of -$28.5 million in Q1 2025.
• The 3-year median for EBITDA is -$14.5 million (2024), against an average of -$16.7 million.
• Peak annual rise in EBITDA reached 25.88% in 2025, while the deepest fall reached 126.38% in 2025.
• Beta Bionics' EBITDA stood at -$18.1 million in 2024, then climbed by 25.88% to -$13.4 million in 2025, then tumbled by 66.91% to -$22.4 million in 2026.
• The last three EBITDA figures came in at -$22.4 million (Q1 2026), -$13.4 million (Q4 2025), and -$14.0 million (Q3 2025), per Business Quant data.